Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2726114 | 1.00 | STK17B (0.41) | STK17BSTK17AAAK1CTSSCTSK | |
| SCHEMBL15238303 | 1.00 | STK17B (0.41) | STK17BSTK17AAAK1CTSSCTSK | |
| SCHEMBL18494391 | 1.00 | STK17B (0.41) | STK17BSTK17AAAK1CTSSCTSK | |
| SCHEMBL15724549 | 0.89 | STK17B (0.44) | STK17BSTK17AAAK1SYKPCSK9 | |
| SCHEMBL21967068 | 0.88 | — | — | |
| SCHEMBL21967069 | 0.88 | — | — | |
| SCHEMBL2723400 | 0.87 | STK17B (0.43) | STK17BSTK17AAAK1SYK | |
| SCHEMBL18495143 | 0.87 | STK17B (0.43) | STK17BSTK17AAAK1SYK | |
| SCHEMBL15238242 | 0.87 | STK17B (0.43) | STK17BSTK17AAAK1SYK | |
| SCHEMBL15249218 | 0.86 | STK17B (0.43) | STK17BSTK17AAAK1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108283644-B | Transient protection of normal cells during chemotherapy | G1治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-108434149-B | HSPC-sparing therapy for Rb-positive abnormal cell proliferation | G1治疗公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-107417691-B | Highly effective anti-neoplastic and anti-proliferative agents | G1治疗公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3653209-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 Therapeutics, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10189851-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189850-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180360841-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3381920-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189851-B2 | CDK inhibitors | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885AAK1 951/4885 |
| US-20180360841-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | STK17B 986/4885STK17A 957/4885AAK1 1704/4885 |
| US-10189850-B2 | CDK inhibitors | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885AAK1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.